Intermediate Risk Prostate Cancer clinical trials

Explore recruiting intermediate risk prostate cancer clinical trials.

Recruiting intermediate risk prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Intermediate Risk Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Effect of neoadjuvant Degarelix on MRI-guided transurethral ultrasound ablation in patients with intermediate-risk prostate cancer: A pilot study

Finland

Human Pharmacology (Phase I)- Other EU CTIS Study details

EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate cancer: the ENHANCE prospective feasibility trial

France

Therapeutic exploratory (Phase II) EU CTIS Study details

DARIUS : A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERMEDIATE UNFAVORABLE RISK PROSTATE CANCER

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Prostate-only, dose-escalated radiotherapy plus concomitant androgen deprivation therapy in primary localized, NCCN high risk and MMAI classifier low or intermediate-risk prostate cancer – a prospective, single-arm, phase II study

Cyprus

Therapeutic exploratory (Phase II) EU CTIS Study details

REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermediate-Risk Prostate Cancer: a Special Focus on Quality of Life and Erectile Function Recovery

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Intermediate Risk Prostate Cancer trials by city

Intermediate Risk Prostate Cancer in Toronto Intermediate Risk Prostate Cancer in Vancouver Intermediate Risk Prostate Cancer in Montreal Intermediate Risk Prostate Cancer in Calgary Intermediate Risk Prostate Cancer in Edmonton Intermediate Risk Prostate Cancer in Ottawa Intermediate Risk Prostate Cancer in Winnipeg Intermediate Risk Prostate Cancer in Quebec City Intermediate Risk Prostate Cancer in Hamilton Intermediate Risk Prostate Cancer in Kitchener Intermediate Risk Prostate Cancer in London Intermediate Risk Prostate Cancer in Halifax Intermediate Risk Prostate Cancer in New York Intermediate Risk Prostate Cancer in Los Angeles Intermediate Risk Prostate Cancer in Chicago Intermediate Risk Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease